Sabine Wittemer-Rump Selected Research

Pasotuxizumab

1/2023	Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy.
1/2021	Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sabine Wittemer-Rump Research Topics

Disease

5	Neoplasms (Cancer) 01/2023 - 11/2016
2	Prostatic Neoplasms (Prostate Cancer) 01/2023 - 01/2021
2	Stomach Neoplasms (Stomach Cancer) 10/2019 - 05/2018
1	Bites and Stings (Sting) 01/2021
1	Thrombocytopenia (Thrombopenia) 10/2019
1	Body Weight (Weight, Body) 10/2019
1	Anemia 10/2019
1	Proteinuria 10/2019
1	Triple Negative Breast Neoplasms 10/2019

Drug/Important Bio-Agent (IBA)

3	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 10/2019 - 11/2016
2	PasotuxizumabIBA 01/2023 - 01/2021
2	aprutumab ixadotinIBA 10/2019 - 11/2016
2	Immunoconjugates (Immunoconjugate)IBA 10/2019 - 11/2016
1	AntigensIBA 01/2023
1	Type 2 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 2)IBA 10/2019
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 10/2019
1	Messenger RNA (mRNA)IBA 05/2018
1	auristatinIBA 11/2016

Therapy/Procedure

2	Castration 01/2023 - 01/2021
1	Immunotherapy 01/2023
1	Therapeutics 01/2021